🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 37 Oxford 10 Leicester 9 Bradford 9 Newcastle upon Tyne 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London37 Oxford10 Leicester9 Bradford9 Newcastle upon Tyne9
All 54 cities
Target enrolment
to
37 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
NCT07810010Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
Sanofi
Phase 2
8,000
Cardiff, Bournemouth, Dorchester, London, Portsmouth, Blackpool, Witney, West Kirby
2026-09-09
Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
NCT07457580Type 1 Diabetes
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
Sanofi
Phase 2
37
Newcastle upon Tyne, London
2025-12-02
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
Sanofi
Phase 2
208
London, Leeds
2025-11-06
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Geographic Atrophy
Sanofi
Phase 1/2
104
London
2025-10-09
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
London
2025-10-01
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
Sanofi
Phase 3
192
London
2025-08-12
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
Sanofi
Phase 2
99
Northwich, Bury, London
2025-07-07
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Bury, Cambridge, London
2025-06-03
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
216
Wigan, London, Taunton
2025-02-06
Active, closed
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667Neovascular Age-related Macular Degeneration
Sanofi
Phase 1/2
66
London, Liverpool
2024-11-21
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Cambridge, Glasgow, Bradford, Chertsey, London
2024-09-30
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
London, Inverness, Oxford
2024-08-21
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
Sanofi
Phase 3
1,541
Portsmouth, Leicester, London, Glasgow
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
Sanofi
Phase 3
260
Cardiff, London, Leeds, Manchester, Newcastle upon Tyne
2024-01-23
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
London, Edinburgh, Sheffield
2023-04-03
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Cambridge, London, Warrington
2022-11-25
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
Sanofi
Phase 3
104
London
2022-05-03
Active, closed
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906Gaucher's Disease Type III
Sanofi
Phase 3
43
London
2022-04-18
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
Sanofi
Phase 3
122
Cambridge, London, Salford
2022-03-11
Active, closed
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)
Sanofi
Phase 2
22
Leeds, London
2021-12-07
Active, closed
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776Glycogen Storage Disease Type II
Sanofi
Phase 3
17
London, Manchester
2021-09-01
Active, closed
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
NCT04848779Glycogen Storage Disease Type II
Sanofi
Observational
16
London, Manchester
2021-06-10
Active, closed
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409Plasma Cell Myeloma
Sanofi
Phase 3
337
Bournemouth, London, Leicester, Southampton
2020-06-16
Recruiting
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469Juvenile Idiopathic Arthritis
Sanofi
Phase 2
51
London, Leeds, Liverpool
2018-08-09
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.